Update on antibacterial and antifungal drugs - Can we master the resistance crisis?

Current Opinion in Pharmacology

Volumn 11, Issue 5, 2011, Pages 429-432

  Theuretzbacher, Ursula ^a   Mouton, Johan W ^b  

^a Center For Anti Infective Agents Vienna   (Austria)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; COLISTIMETHATE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; DRUG DOSE REGIMEN; DRUG RESEARCH; DRUG USE; HUMAN; INFECTION RESISTANCE; LOADING DRUG DOSE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW;

EID: 80053114956     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2011.08.002     Document Type: Editorial

References (15)

1. G. Alvan, C. Edlund, and A. Heddini The global need for effective antibiotics - a summary of plenary presentations Drug Resist Updat 14 2011 70 76
2. Theuretzbacher U: Accelerating resistance, inadequate antibacterial pipelines and international responses. Curr Pharm Biotechnol 2011, in press.
3. U. Theuretzbacher Resistance drives antibacterial drug development Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07.008
4. L. Poirel, R.A. Bonnin, and P. Nordmann Analysis of the resistome of a multidrug-resistant NDM-1-producing Escherichia coli by high-throughput genome sequencing Antimicrob Agents Chemother 55 2011 4224 4229
5. J.L. Martinez, F. Baquero, and D.I. Andersson Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07.005
6. F. Baquero The 2010 Garrod Lecture: the dimensions of evolution in antibiotic resistance: ex unibus plurum et ex pluribus unum J Antimicrob Chemother 66 2011 1659 1672
7. A.J. Stewardson, B. Huttner, and S. Harbarth At least it won't hurt: the personal risks of antibiotic exposure Curr Opin Pharmacol 2011 10.1016/j.coph.2011.06.011
8. J.W. Mouton, P.G. Ambrose, R. Canton, G.L. Drusano, S. Harbarth, A. MacGowan, U. Theuretzbacher, and J. Turnidge Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective Drug Resist Updat 14 2011 107 117
9. R. Singh, and V. Tam Optimizing dosage to prevent emergence of resistance - lessons from in vitro models Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07. 009
10. J.G. Pasipanodya, and T. Gumbo A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07.001
11. P.J. Bergen, J. Li, and R. Nation Dosing of colistin - back to basic PK/PD Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07.004
12. A. MacGowan Revisiting Beta lactams - PK/PD improves dosing of old antibiotics Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07.006
13. R. Canton, and P. Ruiz-Garbajosa Co-resistance: an opportunity for the bacteria and resistance genes Curr Opin Pharmacol 2011 10.1016/j.coph.2011.07. 007
14. S. Seyedmousavi, W. Melchers, P.E. Verweij, and J. Mouton Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR Curr Opin Pharmacol 2011 10.1016/j.coph.2011.08.001
15. P.E. Verweij, E. Snelders, G.H.J. Kema, E. Mellado, and W.J.G. Melchers Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 9 2009 789 795